Stroke or transient ischemic attacks (TIA) represent an urgent clinical entity that is not limited only to elderly patients. The underlying causes of stroke and TIA are diverse, with those of cardiovascular origin being among the most prominent. This review seeks to elucidate some of the most important aspects of the disease in the context of emergency and critical care practice.
FeiginVLForouzanfarMHKrishnamurthiR. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Diseases Study 2010. Lancet2014; 383: 245–254.
2.
TsaiCFThomasBSudlowCLM. Epidemiology of stroke and its subtypes in Chinese versus white populations. Neurology2013; 81: 264–272.
3.
AdamsHPJr.BendixenBHKappelleLJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke1993; 24: 35–41.
4.
Kolominsky-RabasPLWeberMGefellerO. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Stroke2001; 32: 2735–2740.
5.
BarbutDLoYJGoldJP. Impact of embolization during coronary artery bypass grafting on outcome and length of stay. Ann Thorac Surg1997; 63: 998–1002.
6.
PugsleyWKlingerLPaschalisC. The detection of microemboli during cardiopulmonary bypass on neuropsychological functioning. Stroke1994; 25: 1393–1395.
7.
BoekenULitmatheJFeindtPGamsE. Neurological complications after cardiac surgery: risk factors and correlations to the surgical procedure. Thorac Cardiovasc Surg2005; 53: 33–36.
8.
NgaageDlCowenMEGriffinS. Early neurological complications after coronary artery bypass grafting and valve surgery in octogenarians. Eur J Cardio Thorac Surg2008; 33: 653–659.
9.
YoonBWBaeHJKangDW. Intracranial artery disease as a risk factor for central nervous system complications of coronary artery bypass graft surgery. Stroke2001; 32: 94–99.
10.
MisfeldMBreretonJLSweetmanEDoigGS. Neurologic complications after off-pump coronary artery bypass grafting with and without aortic manipulation: meta-analysis of 11398 cases from 8 studies. J Thorac Cardiovasc Surg2011; I42e: 1–7.
11.
TarakjiKGSabikJF3rdBhudiaSK. Temporal onset, risk factors and outcomes associated with stroke after coronary artery bypass grafting. JAMA2011; 305: 381–390.
12.
WarwickTKaliMCarterW. Effect of neurology consults on outcomes for patients suffering transient ischemic attacks after coronary artery bypass grafting. Am J Med Qual2008; 23: 457–464.
13.
GoldsteinLBMatcharDBHoff-LindquistJ. VA Stroke study: neurologist care is associated with increased testing but improved outcomes. Neurology2003; 61: 792–796.
14.
LalaniTChuVHParkLP. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med2013; 173: 1495–1504.
15.
TleyjehIMGhomrawiHMSteckelbergJM. The impact of valve surgery on 6-month mortality in left-sided infective endocarditis. Circulation2007; 115: 1721–1728.
16.
BademosiOFalaseAOJalyesimiFBademosiA. Neuropsychiatric manifestations of infective endocarditis: a study of 95 patients at Ibadan, Nigeria. J Neurol Neurosurg Psychiatry1976; 39: 325–329.
17.
HartRGFosterJWLutherMFKanterMC. Stroke in infective endocarditis. Stroke1990; 21: 695–700.
18.
HeiroMNikosklelainenJEngblomE. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Int Med2000; 160: 2781–2787.
19.
JonesHRSiekertRGGeraciJE. Neurologic manifestations of bacterial endocarditis. Ann Int Med1969; 71: 21–28.
20.
AngstwurmKBorgesACHalleE. Neurological complications of infective endocarditis. Article in German. Der Nervenarzt2004; 75: 734–741.
21.
Garcia-CabreraEFernandez-HidalgoNAlmiranteB. Neurological complications of infective endocarditis: risk factors, outcome and impact of cardiac surgery: a multicenter observational study. Circulation2013; 127: 2272–2284.
22.
SonnevilleRMirabelMHajageD. Neurologic complications and outcomes of infective endocarditis in critically ill patients: The ENDOcardite and REAnimation prospective multicenter study. Crit Care Med2011; 39: 1474–1481.
23.
WolfPAAbbottRDKannelWB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke1991; 22: 983–988.
24.
SkanesACHealeyJSCairnsJA. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol2012; 28: 125–136.
25.
CammAJKirchhofPLipGY. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J2010; 31: 2369–2429, Erratum in: Eur Heart J2011; 32: 117.
26.
SannaTDienerHCPassmanRS. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med2014; 370: 2478–2486.
27.
GageBFWatermanADShannonW. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA2001; 285: 2864–2870.
28.
PistersRLaneDANieuwlaatR. A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. The Euro Heart Survey. Chest2010; 138: 1093–1100.
29.
ConnollySJEzekowitzMDYusufS. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009; 361: 1139–1151.
30.
ConnollySJEzekowitzMDYusufS. Newly identified events in the RE-LY trial. N Engl J Med2010; 363: 1875–1876.
31.
PatelMRMahaffeyKWGargJ. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011; 365: 883–981.
32.
GrangerCBAlexanderJHMcMurrcayJJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011; 365: 981–992.
33.
ManthaSAnsellJ. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost2012; 108: 476–484.
34.
PisonLPotparaTSChenJ. Scientific Initiative Committee, European Heart Rhythm Association. Left atrial appendix closure indications, techniques and outcomes: results of the European Heart Rhythm Association. Europace2015; 17: 642–646.
35.
HandleyAJKosterRMonsieursKPerkinsGD. European resuscitation council guidelines for resuscitation 2005. Section 2. Adult basic life support and use of automated external defibrillators. Resuscitation2005; 67: 7–23. Erratum in: Resuscitation2006; 69: 351
36.
WijclicksEFHijdraAYoungGB. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology2006; 67: 203–210.
37.
CronbergTRundgrenMWesthallE. Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. Neurology2011; 77: 623–630.
38.
HeradstveitBELarssonEMSkeidsvollH. Repeated magnetic resonance imaging and cerebral performance after cardiac arrest – a pilot study. Resuscitation2011; 82: 549–555.
ZandbergenECde HaanRJStoutenbeekCP. Systematic review of early prediction of poor outcome in anoxic-ischaemic coma. Lancet1998; 352: 1808–1812.
41.
RundgrenMWesthallECronbergT. Continuous amplitude-integrated electroencephalogram predicts outcome in hypothermia treated cardiac arrest patients. Crit Care Med2010; 38: 1838–1844.
42.
OksanenTTainenMSkrifvarsMB. Predictive power of serum NES and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. Resuscitation2009; 80: 165–170.
43.
RundgrenMKarlssonTNielsenN. Neuron specific enolase and S-100B as predictors of outcome after cardiac arrest and induced hypothermia. Resuscitation2009; 80: 764–790.
44.
BottigerBWMobesSGlatzerR. Astroglial protein S-100B is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation2001; 103: 2694–2698.
45.
MortbergEZetterbergHNordmarkJ. S-100B is superior to neuron specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation. Resuscitation2011; 82: 26–31.
46.
RandallJMortbergEProvuncherGK. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation2013; 84: 351–356.
47.
StrotmannJ. Cardiac tumors – clinical symptoms, diagnostic approaches and therapeutic aspects. Article in German. Med Klinik2008; 103: 175–180.
48.
ReynenK. Frequency of primary tumors of the heart. Am J Cardiol1996; 77: 107.
Perez AndreuJParrillaGArribasJM. Neurological manifestations of cardiac myxoma: expereince in a referral hospital. Neurologia2013; 28: 529–534.
51.
ZhangTZhangXiZhangXu. Management of multiple embolization arising from atrial myxoma. Ann Thorac Surg2012; 94: 646–648.
52.
KaplanS. Congenital heart disease in adolescents and adults. Natural and postoperative history across age groups. Cardiol Clin1993; 11: 543–556.
53.
JohanssonMCErikssonPGuronCWDellborgM. Pitfalls in diagnosing PFO: characteristics of false-negative contrast injections during transesophageal echocardiography in patients with patent foramen ovales. J Am Soc Echocardiogr2010; 23: 1136–1142.
54.
WayangankarSAPatelJLatifFSivaramC. Right atrial septal pouch – a potential nidus for thrombosis. Echocardiography2012; 29: E1–4.
55.
HandkeMHarloffAOlschewskiM. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med2007: 357: 2262–2268.
56.
FurlanAJReismanMMassaroJ. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med2012; 366: 991–999.
57.
CarrollJDSaverJLThalerDE. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med2013; 368: 1092–1100.
58.
MeierBKalesanBMattleHP. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med2013; 368: 1083–1091.
59.
WeinreichDJBurkeJFPauelttoFJ. Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Int Med1984; 100: 789–794.
60.
StrattonJRResnickAD. Increased embolic risk in patients with left ventricular thrombi. Circulation1987; 75: 1004–1011.
61.
VaitkusPTBarnathanES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. JACC1993; 22: 1004–1009.
62.
DelewiRZijlstraFPiekJJ. Left ventricular thrombus formation after acute myocardial infarction. Heart2012; 98: 1743–1749.
63.
HornerNSheenLLeeR. Idiopathic massive left ventricular thrombus in HIV patient. J Cardiothorac Surg2012; 7: 65.
64.
IyverAMarneyLIppSBoughG. Recurrent left ventricular thrombus in Crohn’s disease: a rare presentation. Asian Cardiovasc Thorac Ann2012; 22: 86–88.
65.
SrichaiMBJunorCRodriguezLL. Clinical, imaging and pathological characteristics of left ventricular thrombus: a comparison of contrast enhanced magnetic resonance imaging, transthoracic echocardiography and transesophageal echocardiography with pathological validation. Am Heart J2006; 152: 75–84.
66.
JohannessenKANordrehaugJEvon der LippeGVollsetSE. Risk factor for embolisation in patients with left ventricular thrombi and acute myocardial infarction. Br Heart J1988; 60: 104–110.
67.
LeeJMParkJJJungHW. Left ventricular thrombus and subsequent thromboembolism. Comparison of anticoagulation, surgical removal and antiplatelet agents. J Atheroscler Thromb2013; 20: 73–93.
68.
SheikhzadehAEhlermannP. Atheromatous disease of the thoracic aorta and systemic embolism. Clinical picture and therapeutic challenge. Z Kardiol2004; 93: 10–17.
69.
HarloffASimonJBrendeckeS. Complex plaques in the proximal descending aorta: an underestimated embolic source of stroke. Stroke2010; 41: 1145–1150.
70.
OkuraHKataokaTYoshiyamaM. Aortic atherosclerotic plaque and long-term prognosis in patients with atrial fibrillation. Circ J2013; 77: 68–72.
71.
KatsanosAHGiannopoulosSKosmidouM. Complex atheromatous plaques in the descending aorta and the risk of stroke: a systematic review and meta-analysis. Stroke2014; 45: 1764–1770.
72.
LazarRMShapiroPAJaskiBE. Neurological events during long-term mechanical circulatory support of heart failure: the randomized evaluation of mechanical assistance for the treatment of congestive heart failure. (REMATCH) experience. Circulation2004; 109: 2423–2427.
73.
PolitoANettoRSoldatiM. Neurological complications during pulsatile ventricular assistance with the Berlin Heart EXCOR in children: incidence and risk factors. Artific Organs2013; 37: 851–856.
74.
BoyleAJRussellSDTeutebergJJ. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant2009; 28: 881–887.
75.
JohnRKamdarFLiaoK. Low thromboembolic risk for patients with HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg2008; 136; 1318–1323.
76.
SlaterJPRoseEALevinHR. Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg1996; 62: 1321–1327.
77.
RossiMSerrainoGFJiritanoFRenzulliA. What is the optimal anticoagulation in patients with a left ventricular assist device?Interact Cardiovasc Thorac Surg2012; 15: 733–740.
78.
BerkhemerOAFransenPSBeumerD. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med2015; 372: 11–20.
79.
SandiumengeADiazEBodiMRelloJ. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of “The Tarragona Strategy”. Intensive Care Med2003; 29: 876–883.
80.
Engel-NitzNMSanderSDHarleyCReyCGShahH. Costs and outcomes of noncardioembolic ischemic stroke in a managed care population. Vasc Health Risk Manag2010; 6: 905–913.
